---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-016245"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:23:27.818283+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies

## Summary
- SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.
- FDA clearance allows first-in-human study in patients with B-cell lymphomas and leukemias.
- Company expects initial clinical data from SC291 study later in 2023.
- Plans to submit a second IND this year for SC262, a CD22-targeted allogeneic CAR T therapy.

## SEC filing metadata
- accession: 0001193125-23-016245
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312523016245/0001193125-23-016245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312523016245/d642303d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-016245
- JSON: https://secwatch.observer/filing/0001193125-23-016245.json
- Plain text: https://secwatch.observer/filing/0001193125-23-016245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.